Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 527

1.

Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.

Jeong JY, Kim KS, Moon JS, Song JA, Choi SH, Kim KI, Kim TH, An HJ.

Apoptosis. 2013 Apr;18(4):509-20. doi: 10.1007/s10495-013-0807-9.

2.

Silencing Wnt2B by siRNA interference inhibits metastasis and enhances chemotherapy sensitivity in ovarian cancer.

Wang H, Fan L, Xia X, Rao Y, Ma Q, Yang J, Lu Y, Wang C, Ma D, Huang X.

Int J Gynecol Cancer. 2012 Jun;22(5):755-61. doi: 10.1097/IGC.0b013e3182540284.

PMID:
22635028
3.

Acquisition of paclitaxel resistance via PI3K‑dependent epithelial‑mesenchymal transition in A2780 human ovarian cancer cells.

Du F, Wu X, Liu Y, Wang T, Qi X, Mao Y, Jiang L, Zhu Y, Chen Y, Zhu R, Han X, Jin J, Ma X, Hua D.

Oncol Rep. 2013 Sep;30(3):1113-8. doi: 10.3892/or.2013.2567. Epub 2013 Jun 26.

PMID:
23807572
4.

Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway.

Chang MC, Chen CA, Hsieh CY, Lee CN, Su YN, Hu YH, Cheng WF.

Biochem J. 2009 Dec 10;424(3):449-58. doi: 10.1042/BJ20082196.

PMID:
19747165
5.

Dexamethasone inhibits the effect of paclitaxel on human ovarian carcinoma xenografts in nude mice.

Hou WJ, Guan JH, Dong Q, Han YH, Zhang R.

Eur Rev Med Pharmacol Sci. 2013 Nov;17(21):2902-8.

6.

RNA interference-mediated silencing of the phosphatidylinositol 3-kinase catalytic subunit attenuates growth of human ovarian cancer cells in vitroand in vivo.

Zhang X, Deng HX, Zhao X, Su D, Chen XC, Chen LJ, Wei YQ, Zhong Q, Li ZY, He X, Yi T.

Oncology. 2009;77(1):22-32. doi: 10.1159/000218201. Epub 2009 May 12.

PMID:
19440000
7.

Simultaneous inhibition of the mitogen-activated protein kinase kinase and phosphatidylinositol 3'-kinase pathways enhances sensitivity to paclitaxel in ovarian carcinoma.

Kawaguchi W, Itamochi H, Kigawa J, Kanamori Y, Oishi T, Shimada M, Sato S, Shimogai R, Sato S, Terakawa N.

Cancer Sci. 2007 Dec;98(12):2002-8. Epub 2007 Sep 26.

8.

The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.

Le XF, Mao W, He G, Claret FX, Xia W, Ahmed AA, Hung MC, Siddik ZH, Bast RC Jr.

J Natl Cancer Inst. 2011 Sep 21;103(18):1403-22. doi: 10.1093/jnci/djr280. Epub 2011 Aug 2.

9.

Notch3-specific inhibition using siRNA knockdown or GSI sensitizes paclitaxel-resistant ovarian cancer cells.

Kang H, Jeong JY, Song JY, Kim TH, Kim G, Huh JH, Kwon AY, Jung SG, An HJ.

Mol Carcinog. 2016 Jul;55(7):1196-209. doi: 10.1002/mc.22363. Epub 2015 Jul 24.

PMID:
26207830
10.

Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells.

Kim SH, Juhnn YS, Song YS.

Ann N Y Acad Sci. 2007 Jan;1095:82-9.

PMID:
17404021
11.

Ursolic acid inhibits growth and induces apoptosis in gemcitabine-resistant human pancreatic cancer via the JNK and PI3K/Akt/NF-κB pathways.

Li J, Liang X, Yang X.

Oncol Rep. 2012 Aug;28(2):501-10. doi: 10.3892/or.2012.1827. Epub 2012 May 22.

PMID:
22641480
12.

Alpha-tomatine synergises with paclitaxel to enhance apoptosis of androgen-independent human prostate cancer PC-3 cells in vitro and in vivo.

Lee ST, Wong PF, Hooper JD, Mustafa MR.

Phytomedicine. 2013 Nov 15;20(14):1297-305. doi: 10.1016/j.phymed.2013.07.002. Epub 2013 Aug 4.

PMID:
23920276
13.

Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway.

Meng Q, Xia C, Fang J, Rojanasakul Y, Jiang BH.

Cell Signal. 2006 Dec;18(12):2262-71. Epub 2006 Jun 2.

PMID:
16839745
14.

Mechanisms of paclitaxel-induced apoptosis in an ovarian cancer cell line and its paclitaxel-resistant clone.

Sugimura M, Sagae S, Ishioka S, Nishioka Y, Tsukada K, Kudo R.

Oncology. 2004;66(1):53-61.

PMID:
15031599
15.

[Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].

Tang X, Lu M, Li C, Deng S, Li M.

Zhonghua Fu Chan Ke Za Zhi. 2014 Jul;49(7):517-22. Chinese.

PMID:
25327734
16.

Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.

Tong L, Chen W, Wu J, Li H.

Anticancer Drugs. 2014 Mar;25(3):244-54. doi: 10.1097/CAD.0000000000000047.

PMID:
24275314
17.

Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFκB pathway.

Yang YI, Lee KT, Park HJ, Kim TJ, Choi YS, Shih IeM, Choi JH.

Carcinogenesis. 2012 Dec;33(12):2488-98. doi: 10.1093/carcin/bgs302. Epub 2012 Oct 1.

PMID:
23027625
19.

Smac peptide potentiates TRAIL- or paclitaxel-mediated ovarian cancer cell death in vitro and in vivo.

Mao HL, Pang Y, Zhang X, Yang F, Zheng J, Wang Y, Liu P.

Oncol Rep. 2013 Feb;29(2):515-22. doi: 10.3892/or.2012.2132. Epub 2012 Nov 9.

PMID:
23151974
20.

Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.

Yang YI, Kim JH, Lee KT, Choi JH.

Gynecol Oncol. 2011 Dec;123(3):588-96. doi: 10.1016/j.ygyno.2011.08.031. Epub 2011 Sep 25.

PMID:
21945308

Supplemental Content

Support Center